Bristol-Myers Squibb Company (BMY) Stock Price, Quote & News

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic mel...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 609 252 4621

Website: www.bms.com

Address:

Route 206 & Province Line Road, Princeton, United States

55X_ROI_Q1_2026 Sep. 14 at 2:08 PM

$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.

0 · Reply

peacewealth7447 Sep. 14 at 10:45 AM

$SLS $JNJ $BMY $CELG

0 · Reply

jamesmckevitt Sep. 14 at 10:44 AM

$SLS just a quick reminder: Michael Frascello of $JNJ has been studying GPS/REGAL for 1.5 years called it a “game changer” in AML. Katherine Bach Kalin on the board of SLS was part of $BMY huge 74b purchase of $CELG and purchase a huge amount of shares 9 months ago. Michael Anglestein of AstraZenica also stated GPS was a game changer for AML patients. Not one of the board have sold a single share either, I’m down; but not out!

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:52 AM

$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 7:01 AM

$SLS $ABBV $BMY Viale-M, T and C Failed

0 · Reply

55X_ROI_Q1_2026 Sep. 14 at 5:07 AM

$SLS $ABBV $BMY Viale-M T and C Failed

1 · Reply

55X_ROI_Q1_2026 Sep. 13 at 10:58 PM

$SLS The $ABBV $BMY People Know its GPs. This current short rigged $2.3B Market cap isn't even Close to What is Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. https://www.reddit.com/r/sellasLifescience/comments/1weo6k2/comment/p9fbhtj/?screen_view_count=1

0 · Reply

55X_ROI_Q1_2026 Sep. 13 at 6:23 PM

$SLS at 60 events the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IMMUNE RESPONSE DATA! Unblinded Actual Median Overall Survival and Immune Response data from the ongoing P3. $ABBV $BMY Own BAT - they all Know Gps is doing what its done in all 7 prior trials, including 2 Phase 2’s for AML REMISSION MAINTENANCE. and Yes BAT Failed 3 large P3’s and 2 for AML MAINTENANCE - Viale-M - Viale-T FAILED.

0 · Reply

Jwa68 Sep. 13 at 12:45 AM

$COYA $XBI $BMY Remember this previous post. Sticking to my 🔫 Things can change in a split second.

0 · Reply

BioRich Sep. 12 at 4:37 PM

$SLS A lot of you are VERY confused today. We've had drops before, but why is this one different? Why does this feel like doom? Simple: Reality Before yesterday, many have felt it. Many of you started to believe it. Many of you started to venture into the "could it be" territory. And then it hit. Perfect storm. Market up, $SLS tanking. - CEO self-imposed Quiet Period feels like cowardness and hiding - Models that so many relied on are now showing a coin toss - Reality that the run up was tied to tutes capitalizing on a dead ticker - Reality that Shorts remain strong and appear in more control - Reality that the hype was from 10 ad hoc patients of an AML study - Reality that the CEO has been suspect since jump street -Reality that competitors $MRK and $BMY collaborated with $SLS and walked before the collab was complete - Reality $SLS's team history is one of legal and regulatory concerns - Reality that all the BS you thought Bears shared now makes complete sense. $XBI

1 · Reply

Here are the stocks to favor in the fourth quarter — and those you should avoid

AAPL ABT ADBE AMZN AVGO BAC BMY

Sep 8, 2026, 7:14 AM EDT - 6 days ago

Market Cap	130.39B
Revenue (ttm)	48.19B
Net Income (ttm)	7.05B
EPS (ttm)	N/A
PE Ratio	9.93
Forward PE	9.28
Profit Margin	14.64%
Debt to Equity Ratio	1.93

Volume	7,529,800
Avg Vol	12,444,174
Day's Range	N/A - N/A
Shares Out	2.04B
Stochastic %K	25%
Beta	0.22
Analysts	Sell
Price Target	$66.30